The Australian Translational Genomics Centre (ATGC) is the first genomic diagnostic service in Queensland, and one of the largest programs of its kind in Australasia, providing whole-exome or whole-genome sequencing and microarray services. The ATGC is a partnership between Queensland University of Technology (QUT), Metro South Hospital and Health Service, and Pathology Queensland.
The facility will offer rapid and comprehensive screening for cancer mutations, identify specific mutational profiles at patient diagnosis required for inclusion in frontline therapeutic clinical trials, reduce resources needed to introduce tests for new genetic variants and may lead to new cancer management protocols based on the primary molecular causes of the cancer. Each year, more than 2,000 Queenslanders will now have access to DNA sequencing technology to identify cancer-causing genetic mutations, which will lead to better treatment outcomes, with potentially fewer side-effects and better survival rates for patients with cancer.
The ATGC is NATA-accredited and will provide next-generation sequencing (NGS) pathology service to Metro South HHS, including whole-exome and whole-genome DNA sequencing, RNA sequencing, as well as SNP microarrays and panels amongst other genomic investigational methods. In addition to diagnostic testing, the ATGC also performs sequencing for research projects funded through grants from Government agencies and non-government organisations or in collaboration with industry partners. The ATGC is located on Level 2 of R-wing at the Princess Alexandria Hospital (PAH) Campus, Woolloongabba, Queensland, Australia.
To find out more about the services provided by the ATGC and how to submit tumour samples for sequencing, bioinformatic analysis and clinical reporting please email email@example.com or call +61 7 3443 7280.